NDA 210303 · Cipla USA
Zemdri
Plazomicin Sulfate · Intravenous
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jun 25, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
2 Phase 3, 0 recruiting
FAERS reports
3
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NEPHROTOXICITY, OTOTOXICITY, NEUROMUSCULAR BLOCKADE and FETAL HARM Nephrotoxicity has been reported with ZEMDRI. The risk of nephrotoxicity is greater in patients with impaired renal function, the elderly, and in those receiving concomitant nephrotoxic medications. Assess creatinine clearance in all patients prior to initiating therapy and daily during therapy [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] . Therapeutic Drug Monitoring (TDM) is recommended for complicated urinary tract infection (cUTI) patients with CLcr less than 90 mL/min to avoid potentially toxic levels [see Dosage and Administration (2.3 , 2.4) ] . Ototoxicity, manifested as hearing loss, tinnitus, and/or vertigo, has been reported with ZEMDRI. Symptoms of aminoglycoside-associated ototoxicity may be irreversible and may not become evident until after completion of therapy....
What it is approved for
From the label in effect Dec 20, 2024.
1. INDICATIONS AND USAGE ZEMDRI is an aminoglycoside antibacterial indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis. ( 1.1 ) As only limited clinical safety and efficacy data are available, reserve ZEMDRI for use in patients who have limited or no alternative treatment options. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain effectiveness of ZEMDRI and other antibacterial drugs, ZEMDRI should be used only to treat infections that are proven or strongly suspected to be caused by susceptible microorganisms. ( 1.2 ) 1.1 Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ZEMDRI is indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible microorganism(s): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , and Enterobacter cloacae . As only limited clinical safety and efficacy data for ZEMDRI are currently available, reserve ZEMDRI for use in cUTI patients who have limited or no alternative treatment options [see Clinical Studies (14.1) ]. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEMDRI and other antibacterial drugs, ZEMDRI should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: ZEMDRI is an antibacterial drug [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 25, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- ZEMDRI · PLAZOMICIN SULFATE EQ 500MG BASE/10ML (EQ 50MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Plazomicin" as an intervention, any sponsor and status, largest first.
- A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)Pivotal-lookingCompleted
Achaogen, Inc.Industry
NCT02486627 · 609 participants · Start Jan 11, 2016 · Primary completion Sep 22, 2016
Drug: plazomicin; meropenem and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis
- A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)Pivotal-lookingCompleted
Achaogen, Inc.Industry
NCT01096849 · 145 participants · Start Jul 13, 2010 · Primary completion Apr 3, 2012
Drug: levofloxacin; plazomicin and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis
- A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)Pivotal-lookingCompleted
Achaogen, Inc.Industry
NCT01970371 · 69 participants · Start Sep 16, 2014 · Primary completion Aug 18, 2016
Drug: plazomicin; colistin and 3 more · For: Bloodstream Infections (BSI) Due to CRE; Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE; Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE and 2 more
- A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy VolunteersCompleted
Achaogen, Inc.Industry
NCT01514929 · 64 participants · Start Oct 2011
Drug: ACHN-490 Injection; ACHN-490 Injection and 2 more · For: Cardiac Effects in Normal Healthy Volunteers
Sites: West Bend, Wisconsin
Achaogen, Inc.Industry
NCT01034774 · 40 participants · Start Jan 2010 · Primary completion Jun 2010
Drug: ACHN-490 Injection; Placebo (normal saline) · For: Healthy Volunteers
- Phase 1 Study for Safety of ACHN-490Completed
Achaogen, Inc.Industry
NCT00822978 · 39 participants · Start Jan 2009 · Primary completion Oct 2009
Drug: ACHN-490 Injection vs placebo · For: Healthy
Sites: Kalamazoo, Michigan
Achaogen, Inc.Industry
NCT01462136 · 24 participants · Start Sep 2011
Drug: ACHN-490 Injection · For: Renal Insufficiency
Achaogen, Inc.Industry
NCT03270553 · 16 participants · Start Aug 31, 2017 · Primary completion Oct 7, 2017
Drug: plazomicin; metformin · For: Healthy Volunteers
Sites: Lincoln, Nebraska
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- acute kidney injury1
- antibiotic level above therapeutic1
- creatinine renal clearance decreased1
- drug effect less than expected1
- gastrointestinal haemorrhage1
- renal failure1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Zemdri (Plazomicin Sulfate) · HCPCS J0291
2024 spending
$165K
Beneficiaries
29
227 claims
Per beneficiary
$5,691
2024 ASP limit $3.60 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $264,734 |
| 2021 | $236,781 |
| 2022 | $125,169 |
| 2023 | $128,523 |
| 2024 | $165,053 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis.
Wagenlehner F, Caballero VR, Maheshwari V, et al. · J Comp Eff Res 2025 · Systematic Review, Network Meta-Analysis
- A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy?
Goodlet KJ, Benhalima FZ, Nailor MD · Antimicrob Agents Chemother 2019 · Systematic Review
- Once-Daily Plazomicin for Complicated Urinary Tract Infections.
Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Equivalence Trial
- Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.
McKinnell JA, Dwyer JP, Talbot GH, et al. · N Engl J Med 2019 · Letter, Multicenter Study
- No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects.
Choi T, Komirenko AS, Riddle V, et al. · Clin Pharmacol Drug Dev 2019 · Clinical Trial, Phase I, Randomized Controlled Trial
- Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
Hung KC, Tsai WW, Hsu CW, et al. · Int J Antimicrob Agents 2023 · Meta-Analysis, Systematic Review
Sponsor: Cipla USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.